Primary hyperparathyroidism and monoclonal gammopathy

Coexistent primary hyperparathyroidism and monoclonal gammopathy, although rare, has been reported previously by a number of investigators. We report four patients with such an occurrence who were seen between 1976 and 1988. Another patient with primary hyperparathyroidism also had multiple myeloma and was in remission for 12 years. These patients represent approximately 1% of the 386 patients with primary hyperparathyroidism seen during the same 12-year period. Although several mechanisms have been proposed to explain this concurrence, we believe it is the result of a chance occurrence. A review of the literature, an estimate of the chance occurrence of coincidental monoclonal gammopathy, benign or malignant, in patients with primary hyperparathyroidism, and some practical implications of this interesting coexistence are presented.     

Simultaneous prepubertal onset of panic disorder, night terrors, and somnambulism

Concurrent acute onset of night terrors, somnambulism, and spontaneous daytime panic attacks meeting the criteria for panic disorder is reported in a 10-year-old boy with a family history of panic disorder. Both the parasomnias and the panic disorder were fully responsive to therapeutic doses of imipramine. A second case of night terrors and infrequent full symptom panic attacks is noted in another 10-year-old boy whose mother has panic disorder with agoraphobia. The clinical resemblance and reported differences between night terrors and panic attacks are described. The absence of previous reports of this comorbidity is notable. It is hypothesized that night terror disorder and panic disorder involve a similar constitutional vulnerability to dysregulation of brainstem altering systems.     

Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride

We conducted a randomized, double-blind, crossover trial of two anticholinergic agents--trihexyphenidyl and tridihexethyl chloride (a quaternary anticholinergic that does not cross the blood-brain barrier)--in patients with acquired nystagmus and measured visual acuity and nystagmus before and at the end of 1 month on each medication. Of the 10 patients admitted to the study, only five completed trials of both drugs due to intolerance of medication or intercurrent illness. Of six patients who completed the trial of trihexyphenidyl, only one showed improvement. Of six patients who completed a trial of tridihexethyl chloride, four showed improvement. We conclude that (1) trihexyphenidyl is not a reliable treatment for acquired nystagmus, although occasional patients may benefit; (2) anticholinergic agents may suppress nystagmus by peripheral rather than central mechanisms; and (3) the side effects of anticholinergic agents limit their effectiveness in the treatment of nystagmus.     

Changes of electrocoagulographic parameters and erythrocyte deformability in multiple myeloma patients on various regimens of polychemotherapy]

Clinical and laboratory indications of hemocoagulatory disorders (according to the data of electrocoagulograph H-334 and red blood cell deformability) were compared for multiple myeloma patients. They received drugs according to 3 different polychemotherapy schemes involving various combinations and doses of cyclophosphamide, vincristine, rubomycin, paphencyl, sarcolysin and prednisolone. Pretreatment measurements in relevant patients revealed severe hemocoagulative and rheologic shifts responsible for hemorrhages, impaired microcirculation and cardiac failure. The most efficient polychemotherapy was found that gained benefit with addition of plasmapheresis. To control the effect of polychemotherapy, its intensity, individual deviations and duration, it is advisable to combine routine tests with citrated plasma electrocoagulography, assessment of AT-III activity and red blood cell deformability indicating hemocoagulative and rheologic disorders.     

The effect of sodium nucleinate on the proliferative and specific activity of hybridoma cells in vitro]

Sodium nucleinate, an officinal preparation (Na PHK), added to the growth medium in concentrations of 10 to 50 micrograms/ml enhanced the growth of hybridoma cells in vitro. Na PHK presence in the cultivation medium in the above concentrations enhanced the specific antibody-producing activity of hybridomas.